DK1715890T3 - CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati - Google Patents

CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati

Info

Publication number
DK1715890T3
DK1715890T3 DK05713358T DK05713358T DK1715890T3 DK 1715890 T3 DK1715890 T3 DK 1715890T3 DK 05713358 T DK05713358 T DK 05713358T DK 05713358 T DK05713358 T DK 05713358T DK 1715890 T3 DK1715890 T3 DK 1715890T3
Authority
DK
Denmark
Prior art keywords
diabetic nephropathy
microalbuminuria
ctgf
therapy
patients
Prior art date
Application number
DK05713358T
Other languages
English (en)
Inventor
Allan Flyvbjerg
Guangjie Guo
David Y Liu
Thomas B Neff
Noelynn A Oliver
William R Usinger
Qingjian Wang
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Application granted granted Critical
Publication of DK1715890T3 publication Critical patent/DK1715890T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
DK05713358T 2004-02-11 2005-02-11 CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati DK1715890T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54412104P 2004-02-11 2004-02-11
US56101804P 2004-04-08 2004-04-08
US57840104P 2004-06-09 2004-06-09
US62080204P 2004-10-20 2004-10-20
PCT/US2005/004367 WO2005077413A1 (en) 2004-02-11 2005-02-11 Ctgf as target for the therapy of diabetic nephropathy

Publications (1)

Publication Number Publication Date
DK1715890T3 true DK1715890T3 (da) 2008-11-17

Family

ID=34865408

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05713358T DK1715890T3 (da) 2004-02-11 2005-02-11 CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati

Country Status (15)

Country Link
US (2) US20050214294A1 (da)
EP (2) EP1715890B1 (da)
CN (1) CN101884789A (da)
AT (1) ATE400297T1 (da)
AU (1) AU2005212371B2 (da)
CA (1) CA2555789A1 (da)
DE (1) DE602005008013D1 (da)
DK (1) DK1715890T3 (da)
ES (1) ES2311973T3 (da)
HK (1) HK1095762A1 (da)
IL (1) IL177437A (da)
NZ (1) NZ549784A (da)
PL (1) PL1715890T3 (da)
PT (1) PT1715890E (da)
WO (1) WO2005077413A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4863548B2 (ja) * 1998-09-08 2012-01-25 ヘンリー フォード ヘルス システム 結合組織増殖因子のモジュレーション、調節および抑制による腎障害の検出、予防および治療方法
US8088381B2 (en) 2005-05-05 2012-01-03 Fibrogen, Inc. Methods of treatment of cardiovascular disease using anti-CTGF agents
EP1968561B8 (en) * 2005-12-22 2010-10-20 Kiacta Sàrl Treatment of diabetic nephropathy
JP2010529947A (ja) * 2006-12-22 2010-09-02 ベラス ヘルス（インターナショナル）リミテッド 代謝性疾患および糖尿病を治療するための方法、化合物、および組成物
CA2697057A1 (en) * 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
EP3081648A1 (en) 2008-08-25 2016-10-19 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
AU2012212110A1 (en) 2011-02-02 2013-08-01 Excaliard Pharmaceuticals, Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
JP6612246B2 (ja) * 2013-11-28 2019-11-27 シーエスエル、リミテッド 腎症を処置する方法
CN111033637B (zh) 2017-08-08 2023-12-05 费森尤斯医疗保健控股公司 用于治疗和评估慢性肾脏疾病的进程的系统和方法
KR20200014684A (ko) * 2018-07-31 2020-02-11 주식회사 레모넥스 Ctgf 발현 억제용 조성물
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN109453191A (zh) * 2018-12-06 2019-03-12 郑州大学第附属医院 GSK-3β抑制剂及在糖尿病肾病干预新靶点的应用
WO2020244540A1 (zh) * 2019-06-04 2020-12-10 江苏恒瑞医药股份有限公司 抗结缔组织生长因子抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5876730A (en) 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
WO1999033878A1 (fr) 1997-12-25 1999-07-08 Japan Tobacco Inc. Anticorps monoclonal contre le facteur de croissance du tissu conjonctif et ses mises en applications medicales
US20010006979A1 (en) 1998-07-08 2001-07-05 Richard Stratton Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
JP4863548B2 (ja) * 1998-09-08 2012-01-25 ヘンリー フォード ヘルス システム 結合組織増殖因子のモジュレーション、調節および抑制による腎障害の検出、予防および治療方法
US6348329B1 (en) * 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
CA2350182A1 (en) 1998-11-06 2000-05-18 Fibrogen, Inc. Connective tissue growth factor (ctgf) and methods of use
AU773278B2 (en) * 1998-12-14 2004-05-20 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
US6706491B1 (en) 1999-04-09 2004-03-16 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by p21
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
AU2002366641A1 (en) * 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
BR0309623A (pt) 2002-04-30 2005-02-09 Alcon Inc Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
EP1687410A4 (en) 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc ANTISENSE OLIGONUCLEOTIDES OPTIMIZED TO TARGET THE KIDNEY

Also Published As

Publication number Publication date
WO2005077413A1 (en) 2005-08-25
ES2311973T3 (es) 2009-02-16
AU2005212371B2 (en) 2010-05-13
HK1095762A1 (en) 2007-05-18
CN101884789A (zh) 2010-11-17
EP1715890B1 (en) 2008-07-09
IL177437A0 (en) 2006-12-10
EP1977762A1 (en) 2008-10-08
DE602005008013D1 (de) 2008-08-21
CA2555789A1 (en) 2005-08-25
ATE400297T1 (de) 2008-07-15
EP1715890A1 (en) 2006-11-02
PT1715890E (pt) 2008-10-17
IL177437A (en) 2013-06-27
AU2005212371A1 (en) 2005-08-25
US20100291098A1 (en) 2010-11-18
US20050214294A1 (en) 2005-09-29
US8314059B2 (en) 2012-11-20
PL1715890T3 (pl) 2009-01-30
NZ549784A (en) 2008-06-30

Similar Documents

Publication Publication Date Title
HK1095762A1 (en) Ctgf as target for the therapy of microalbuminuriain patients with diabetic nephropathy
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
CY2016015I1 (el) Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
CY1110889T1 (el) C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους
WO2006078463A3 (en) Method for treating cardiovascular disease
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
EA200901211A1 (ru) Антигены белка с5 и их применение
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EP1958648A4 (en) THERAPEUTIC PROCESS FOR BLOOD CLEANING DISORDER
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
DK1889920T3 (da) In vitro fremgangsmåde atil identifikation af forbindelse atil cancerterapi
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
CY1110620T1 (el) Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
BR0313588A (pt) Métodos para o tratamento da demência com base em apo e genótipo
ATE557102T1 (de) Methoden zur vorhersage der wirksamkeit von interferon therapie bei multiple sklerose patienten und methoden zur diagnose der krankheit
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
ES1057646Y (es) Protesis perfeccionada para el tratamiento quirurgico de las hernias de la ingle.
IL178120A0 (en) Therapeutic combination for treatment of alzheimers disease